Cargando…

Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas

BACKGROUND: Immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and the programmed cell death protein-1/programmed death-ligand 1 (PD-1/PD-L1) have emerged as promising new targets for cancer therapeutics. While tumor expression of PD-L1 has been shown to have objective responses...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kassardjian, Ari, Shintaku, Peter I., Moatamed, Neda A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909602/ https://www.ncbi.nlm.nih.gov/pubmed/29672601 http://dx.doi.org/10.1371/journal.pone.0195958

Ejemplares similares

Expression of immune checkpoint regulators, programmed death-ligand 1 (PD-L1/PD-1), cytotoxic T lymphocyte antigen 4 (CTLA-4), and indolaimine-2, 3-deoxygenase (IDO) in uterine mesenchymal tumors
por: Samiei, Alireza, et al.
Publicado: (2022)

Programmed Cell Death 1 (PD-1) and Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) in Viral Hepatitis
por: Cho, Hyosun, et al.
Publicado: (2017)

Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas
por: Reddy, Opal L., et al.
Publicado: (2017)

Rigid-body Ligand Recognition Drives Cytotoxic T-lymphocyte Antigen 4 (CTLA-4) Receptor Triggering
por: Yu, Chao, et al.
Publicado: (2011)

Cytotoxic T Lymphocyte–associated Antigen 4 (CTLA-4) Regulates the Unfolding of Autoimmune Diabetes
por: Lühder, Fred, et al.
Publicado: (1998)

The CTLA‐4 immune checkpoint protein regulates PD‐L1:PD‐1 interaction via transendocytosis of its ligand CD80
por: Kennedy, Alan, et al.
Publicado: (2023)

Induction of Cytotoxic T Lymphocyte Antigen 4 (Ctla-4) Restricts Clonal Expansion of Helper T Cells
por: Doyle, Alden M., et al.
Publicado: (2001)

Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators
por: Le Mercier, Isabelle, et al.
Publicado: (2015)

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
por: Qin, Shuang, et al.
Publicado: (2019)

Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
por: Zhang, Hao, et al.
Publicado: (2021)

Expression of PD‐L1 and CTLA‐4 in female urethral carcinoma
por: Ninomiya, Sahoko, et al.
Publicado: (2018)

CTLA-4 and PD-1 Ligand Gene Expression in Epithelial Thyroid Cancers
por: Tuccilli, Chiara, et al.
Publicado: (2018)

Association of Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) and Thyroglobulin (TG) Genetic Variants with Autoimmune Hypothyroidism
por: Patel, Hinal, et al.
Publicado: (2016)

Current Understanding of Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Signaling in T-Cell Biology and Disease Therapy
por: Kim, Gil-Ran, et al.
Publicado: (2022)

Impact of CTLA-4 checkpoint antibodies on ligand binding and Transendocytosis
por: Williams, Cayman, et al.
Publicado: (2022)

Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4
por: Pandey, Pratibha, et al.
Publicado: (2022)

Checkpoint inhibition of PD-L1 and CTLA-4 in a child with refractory acute leukemia
por: Broglie, Larisa, et al.
Publicado: (2019)

Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment
por: Ziogas, Dimitrios C., et al.
Publicado: (2023)

Relationship Between the Expression of PD-1 and CTLA-4 on T Lymphocytes and the Severity and Prognosis of Sepsis
por: Wang, Lang, et al.
Publicado: (2023)

Lack of correlation between the levels of soluble cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and the CT-60 genotypes
por: Purohit, Sharad, et al.
Publicado: (2005)

CTLA-4-mediated posttranslational modifications direct cytotoxic T-lymphocyte differentiation
por: Lingel, Holger, et al.
Publicado: (2017)

Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1
por: Kong, Yi-chi M., et al.
Publicado: (2014)

Cytotoxic T Lymphocyte Antigen 4 (CTLA4) Blockade Accelerates the Acute Rejection of Cardiac Allografts in CD28-deficient Mice: CTLA4 Can Function Independently of CD28
por: Lin, Hua, et al.
Publicado: (1998)

Soluble cytotoxic T-lymphocyte–associated antigen 4 (sCTLA-4) as a potential biomarker for diagnosis and evaluation of the prognosis in Glioma
por: Liu, Jiajia, et al.
Publicado: (2021)

B7-1 or B7-2 Is Required to Produce the Lymphoproliferative Phenotype in Mice Lacking Cytotoxic T Lymphocyte–associated Antigen 4 (CTLA-4)
por: Mandelbrot, Didier A., et al.
Publicado: (1999)

Clonality of CD4(+) Blood T Cells Predicts Longer Survival With CTLA4 or PD-1 Checkpoint Inhibition in Advanced Melanoma
por: Arakawa, Akiko, et al.
Publicado: (2019)

Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
por: Váraljai, Renáta, et al.
Publicado: (2023)

The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition
por: Kreidieh, Firas Y., et al.
Publicado: (2023)

Immune Checkpoint PD-1/PD-L1 CTLA-4/CD80 are Blocked by Rhus verniciflua Stokes and its Active Compounds
por: Li, Wei, et al.
Publicado: (2019)

Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4(+) T Cells
por: Saleh, Reem, et al.
Publicado: (2019)

Association of Cytotoxic T-Lymphocyte Antigen-4 Gene Polymorphism with Type 1 Diabetes Mellitus: In silico Analysis of Biological Features of CTLA-4 Protein on Ethiopian Population
por: Ebrahim, Endris, et al.
Publicado: (2022)

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
por: Callahan, Margaret K., et al.
Publicado: (2015)

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
por: Heinzerling, Lucie, et al.
Publicado: (2016)

Combination of CTLA-4 and PD-1 blockers for treatment of cancer
por: Rotte, Anand
Publicado: (2019)

Inborn Errors of Immunity and Their Phenocopies: CTLA4 and PD-1
por: Hao, Yuwei, et al.
Publicado: (2022)

Association Between Serum Cytotoxic T Lymphocyte Antigen (CTLA)-4 Level and Disease Progression in Patients With Chronic Hepatitis B
por: Darmadi, Darmadi, et al.
Publicado: (2023)

Cytotoxic T Lymphocyte–associated Antigen 4 (CTLA-4) Can Regulate Dendritic Cell–induced Activation and Cytotoxicity of CD8(+) T Cells Independently of CD4(+)T Cell Help
por: McCoy, Kathy D., et al.
Publicado: (1999)

Rational Combination of Parvovirus H1 With CTLA-4 and PD-1 Checkpoint Inhibitors Dampens the Tumor Induced Immune Silencing
por: Goepfert, Katrin, et al.
Publicado: (2019)

Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in mice
por: Affolter, Timothy, et al.
Publicado: (2019)

Unequal distribution of genetically-intact HIV-1 proviruses in cells expressing the immune checkpoint markers PD-1 and/or CTLA-4
por: Fisher, Katie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2qb3gla2nlgcpnmeaoon6svbvp